Expanding on this, Rituximab has also been utilized as a B-cell depleting agent in order to eradicate anti-GM-CSF autoantibodies and subsequently serve as a therapeutic intervention for PAP. The gene discussed is CSF2; the disease is pulmonary alveolar proteinosis.